Overview Technical Risk & rank Quality Results Accounts Filings Options Guidance & governance
Guidance tracker
What IPCALAB guided, and what came next
| Filed | What the filing says | Next results: profit YoY | Revenue | Move on the day |
|---|---|---|---|---|
| 06 Nov 2026 | Ipca Laboratories filed the transcript of its Q2 FY27 earnings conference call held on 5 November 2026 (filed 6 November 2026 under Regulation 30). Management said consolidated revenue grew about 14% to around INR2,910 crores (vs INR2,557 crores), with consolidated EBITDA margin of 22.97% (vs 21.68%) and standalone... NSE copy | No results filed since | ||
| 17 Aug 2026 | Ipca Laboratories filed the transcript of its Q1 FY27 earnings conference call held on August 14, 2026. Management said consolidated revenue grew about 21% to INR2,788 crores from INR2,309 crores, and consolidated EBITDA margin rose to 22.88% from 18.39%. Management said domestic formulation sales grew 13% to about... NSE copy | +32.8 % | +13.8 % | -0.4 % |
| 04 Jun 2026 | Ipca Laboratories filed the transcript of its Q4 FY26 earnings conference call held on 1 June 2026, with MD A.K. Jain and CS Harish Kamath. Management said consolidated FY26 revenue grew about 8% to INR9,646 crores and consolidated EBITDA margin was 20.72% (vs 19.94%); Q4 consolidated EBITDA margin was 20.52%.... NSE copy | +72.3 % | +20.8 % | -3.5 % |
| 18 Feb 2026 | Ipca Laboratories filed the transcript of its Q3 FY26 earnings conference call held on February 16, 2026, under Regulation 30 of the SEBI LODR Regulations. Management said domestic business grew about 12% in Q3 FY26, with IPM growth of about 8.9% in the quarter, and consolidated revenue rose about 6.5% to INR2,245... NSE copy | +341.0 % | +6.3 % | -2.2 % |
| 17 Nov 2025 | Ipca Laboratories filed the transcript of its Q2 FY26 earnings conference call held on 13 November 2025, with Managing Director A.K. Jain and Company Secretary Harish Kamath representing management. Management said domestic formulations grew about 8% in Q2 FY26, with Ipca's market growth outpacing the IPM (Ipca... NSE copy | +31.5 % | +6.6 % | +0.7 % |
| 14 Aug 2025 | Ipca Laboratories filed a transcript of its Q1 FY26 earnings conference call held on 12 August 2025, hosted by DAM Capital. Management said standalone EBITDA margin improved to 23.82% in Q1 FY26 from 22.22% in Q1 FY25, while consolidated EBITDA margin was 18.39% versus 18.52%; standalone net profit rose about 26%... NSE copy | +23.1 % | +8.6 % | +13.6 % |
| 02 Jun 2025 | Ipca Laboratories filed the transcript of its Q4 FY25 earnings conference call held on May 30, 2025, with MD Ajit Kumar Jain and Company Secretary Harish Kamath. Management said consolidated EBITDA margin for FY25 was 18.94% versus 16.72% in FY24, above the around 18% guidance for the year; Q4 consolidated EBITDA... NSE copy | +21.3 % | +10.3 % | +3.0 % |
| 18 Feb 2025 | Ipca Laboratories filed the transcript of its Q3 FY25 post-results earnings conference call held on 13 February 2025, hosted by DAM Capital Advisors. Management (A.K. Jain, Managing Director) said standalone Q3 FY25 EBITDA margin was about 24.25% versus 18.52% in Q3 FY24; consolidated EBITDA margin was about 19.87%... NSE copy | +13.8 % | +10.5 % | -3.1 % |
| 18 Nov 2024 | Ipca Laboratories filed the transcript of its Q2 and H1 FY25 earnings conference call held on November 14, 2024. Management said domestic formulations grew 11% in Q2 FY25, with the company outpacing the IPM market (about 8% per IQVIA) and the acute and chronic segments; market share rose to 2.14% from 2.04% a year... NSE copy | +37.9 % | +9.4 % | -1.8 % |
Filings tagged as guidance, newest first (9 in all), with the company's next results after each: profit and revenue against the same quarter a year before, and the share's move on the results day. Whether the guidance was met is for the reader to judge from both; the site does not score it. The summaries are written by an AI model from the filing and can be wrong - the filing is the source.
Governance
Management, auditors, ratings and legal matters
| Filed | Kind | What the filing says |
|---|---|---|
| 07 Jul 2026 | Credit rating | India Ratings & Research (A Fitch Group Company) reviewed and affirmed Ipca Laboratories' credit ratings. Commercial paper of INR 500 million, maturity up to 365 days, affirmed at IND A1+. Bank loan facilities of INR 22,481.10 million (reduced from INR 25,937.30 million) affirmed at IND AA+/Stable/IND A1+. The CP... NSE copy |
| 26 Jun 2026 | Legal or regulatory | Ipca Laboratories' board approved a Scheme of Amalgamation of its wholly owned subsidiary Krebs Biochemicals & Industries Ltd (Transferor) into Ipca Laboratories (Transferee), under Sections 230-232 of the Companies Act, 2013, with an appointed date of 1 April 2026. Ipca's standalone audited total income for FY... NSE copy |
| 26 Jun 2026 | Legal or regulatory | Ipca Laboratories' board approved a Scheme of Amalgamation of its subsidiary Krebs Biochemicals & Industries Ltd (transferor) into Ipca Laboratories (transferee), under Sections 230-232 of the Companies Act, 2013, with an appointed date of 1 April 2026. Ipca's standalone audited total income for FY ended 31 March... NSE copy |
| 29 May 2026 | Management change | Ipca Laboratories' board, at its meeting held on May 29, 2026, approved audited standalone and consolidated financial results for Q4 and FY ended March 31, 2026, along with a press release on the FY 2025-26 results. Standalone FY2026 revenue from operations was Rs 7,336.75 crore (FY2025: Rs 6,677.92 crore);... NSE copy |
| 29 May 2026 | Management change | Ipca Laboratories filed the outcome of its board meeting held on May 29, 2026, approving audited standalone and consolidated financial results for Q4 and FY ended March 31, 2026. Standalone FY2025-26 revenue from operations was Rs 7,336.75 crore (FY2024-25: Rs 6,677.92 crore); standalone FY2025-26 net profit was Rs... NSE copy |
| 13 Jan 2026 | Legal or regulatory | Board outcome filing (Regulation 30) on 13 January 2026; board meeting ran from 10:15 am to 10:35 am. Ipca Pharmaceuticals Inc, USA (wholly owned subsidiary of the company) proposes to sell its entire shareholding in Bayshore Pharmaceuticals LLC, USA, a dormant step-down subsidiary, to Centaur Pharmaceuticals USA... NSE copy |
| 07 Jul 2025 | Credit rating | India Ratings & Research (A Fitch Group Company) reviewed and affirmed Ipca Laboratories' ratings on its bank facilities and commercial paper. Commercial paper of INR 500 million rated IND A1+ (affirmed); the CP is not carved out of fund-based working capital limits. Fund/non-fund based working capital limit of INR... NSE copy |
| 29 May 2025 | Legal or regulatory | Ipca Laboratories announced outcome of its Board meeting held on 29 May 2025, approving audited standalone and consolidated results for Q4 and FY ended 31 March 2025. Board recommended a final dividend of Rs. 2/- per share (200%) for FY 2024-25, subject to shareholder approval at the ensuing AGM, with 5 August 2025... NSE copy |
| 28 Mar 2025 | Legal or regulatory | Board of Ipca Laboratories approved, on 28 March 2025, the sale of its formulations manufacturing facility at T-139, MIDC, Tarapur, to M/s. V. S. International Pvt. Ltd. on a slump sale basis for Rs. 36.90 crores in cash; the sale is expected to complete on or before 30 June 2025, subject to approvals, and the... NSE copy |
Filings with a management change, a legal or regulatory matter or a credit rating (by their tags), or naming an auditor, a resignation or a pledge of shares; newest first (9 in all). A list of what was filed, not a judgement of the company.